Phase 2 study of abiraterone acetate for castration-resistant androgen receptor-expressing salivary gland cancer

Patients with androgen receptor-positive (AR+) salivary gland cancer (SGC) can benefit from androgen-deprivation therapy (ADT). The best approach after failure of ADT is still unknown. A phase 2 study in Italy evaluated abiraterone acetate plus LHRH agonist as second-line treatment for ADT-resistant, AR+ SGC. Partial response was seen in 21% of patients and disease control in 62.5%. Median duration of response was 5.82 months, median progression-free survival was 3.65 months and median overall survival was 22.47 months. There were no grade 4 or 5 adverse events.